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ABSTRACT: The AAA+ ATPase p97/VCP adopts at least
three conformations that depend on the binding of ADP and
ATP and alter the orientation of the N-terminal protein−
protein interaction (PPI) domain into “up” and “down”
conformations. Point mutations that cause multisystem
proteinopathy 1 (MSP1) are found at the interface of the N
domain and D1-ATPase domain and potentially alter the
conformational preferences of p97. Additionally, binding of
“adaptor” proteins to the N-domain regulates p97’s catalytic activity. We propose that p97/adaptor PPIs are coupled to p97
conformational states. We evaluated the binding of nucleotides and the adaptor proteins p37 and p47 to wild-type p97 and MSP1
mutants. Notably, p47 and p37 bind 8-fold more weakly to the ADP-bound conformation of wild-type p97 compared to the
ATP-bound conformation. However, MSP1 mutants lose this nucleotide-induced conformational coupling because they
destabilize the ADP-bound, “down” conformation of the N-domain. Loss in conformation coupling to PPIs could contribute to
the mechanism of MSP1.
p97/VCP belongs to the AAA+ (ATPase associated withvarious cellular activities) family of enzymes and is a key
regulator of several cellular processes involved in protein
homeostasis.1−3 p97 forms a barrel-like homohexamer with
each subunit consisting of tandem ATPase domains (D1 and
D2).4,5 The ATPase domains are sandwiched by N- an C-
terminal domains, which function as protein−protein inter-
action (PPI) sites.6,7 Binding of a network of adaptor proteins
to the terminal domains directs p97 toward a particular cellular
process; e.g., binding of the adaptor p47 directs p97 to function
in membrane fusion, whereas binding to NPL4/UFD1 targets
p97 to ER-associated degradation.1,8 Recent high-resolution
cryo-EM structures of p97 reveal that this enzyme adopts at
least three conformations that depend on the binding of ADP
and ATPγS in its two ATPase domains.9 Conformational
changes include the orientation of the N-terminal PPI domain,
which can adopt an “up” conformation in the presence of
ATPγS and a “down” conformation when ADP is bound.10
However, we still lack mechanistic details about how the
nucleotide-induced conformational changes in p97 affect PPIs.
Point mutations in p97 cause the multisystem proteinopathy
type 1 (MSP1) disorder, also called inclusion body myopathy
associated with Paget’s disease and frontotemporal dementia/
amyotrophic lateral sclerosis (IBMPFD/ALS).11,12 MSP1
mutations cluster at the ND1 interface to affect p97’s
function.13 Although these mutations do not alter the
hexameric state of p97, they cause an overall ∼3-fold increase
in p97 D2 ATPase activity13−15 and decrease the affinity of
ADP to the isolated ND1 domains of p97.10,16 In addition,
immunoprecipitation studies found that MSP1 disease
mutations caused differential binding of adaptor proteins to
the N-domain of p97 in cells.15,17,18 However, this differential
immunoprecipitation was not observed in vitro using purified
proteins.19−21 This discrepancy may be resolved by accounting
for the ATPase hydrolysis cycle, because the catalytic activities
of wild-type (WT) p97 and MSP1 mutants differ when
complexed with the adaptors p37 and p47.22 p37 and p47 are
trimeric proteins that contain two conserved domains: a central
SEP domain that is involved in trimerization and a ubiquitin
regulatory X (UBX) domain that binds to the N-domain of
p97. In addition, p47 also contains an N-terminal ubiquitin-
associated (UBA) domain that binds ubiquitin. Given the
nucleotide-dependent conformational changes that occur in
both the D1 and D2 domains of p97,9 and the fact that
nucleotide binding to one ATPase domain is coupled with
ATPase activity in the other,16,23 we sought to evaluate the
effect of MSP1 disease mutations on nucleotide binding and on
the binding of p37 and p47 adaptor proteins in the context of
full-length (FL) p97. Results presented here provide insights
into how p97’s conformational changes regulate PPIs in WT
and disease mutants.
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We first assessed nucleotide binding to FL WT p97 and the
MSP1 mutations R155H and A232E. These two mutations
were chosen because the Arg155 mutation is the most
prevalent, and the A232E is associated with an earlier onset
and more severe form of the disease.17 Binding of nucleotides
to MSP1 mutations was previously determined by isothermal
titration calorimetry (ITC), using a construct containing only
the N and D1 domains of p97.10,16 Here, we measure
nucleotide binding to FL p97 using surface plasmon resonance
(SPR), which is sensitive enough to detect the binding at both
the D1 and D2 ATPase sites. We have previously shown that
the D1 domain binds ADP and ATP ∼40-fold more tightly
than the D2 domain (130 nM vs 5 μM) in the context of full-
length protein.23
Interestingly, unlike the previous ITC binding results on the
ND1 truncation of p97, which showed a decrease in ADP
affinity in the D1 domain of the R155H and A232E mutants,16
we did not observe a significant difference in the dissociation
constants (KD’s) for ADP binding to either the D1 or D2
domains in FL WT or mutant p97 proteins (Table 1, Figure
S1A). However, the off-rates for ADP binding were 2−3-fold
faster for both the D1 and D2 domains in the R155H and
A232E mutants compared to WT, indicating ADP is more
easily exchanged in both domains in the mutants (Table 1). In
contrast, binding of ATP and ATPγS showed similar kinetic
parameters for WT and the MSP1 mutants (Figure S1B,C and
Table S1).
To confirm that immobilization of the p97 proteins did not
alter the nucleotide binding potential or conformational
flexibility of p97, we assessed nucleotide binding using a
fluorescence anisotropy assay. We measured binding of EDA-
ADP-ATTO-448 and BODIPY-FL-ATP probes to FL WT p97
and R155H and A232E mutants (Figure S2). This assay only
reports binding to the D1 domain.23 Similar to the SPR results,
the KD value for EDA-ADP-ATTO-448 binding to the D1
domain in FL WT p97 was very similar to the binding affinities
to the D1 domain of the R155H and the A232E mutant (Table
1). In addition, binding affinities for BODIPY-FL-ATP to the
D1 domain were within 1.6-fold for WT p97 and the MSP1
mutants (Figure S2).
To determine if MSP1 mutations altered the coupling of
nucleotide binding between domains, we measured nucleotide
binding to WT and R155H p97 proteins that contain Walker A
mutations. Walker A mutations K251A in the D1 domain
(K251AD1) and K524A in the D2 domain (K524AD2) prevent
nucleotide binding to the respective ATPase domain. We found
that the R155H−K524AD2 mutation (where the D2 domain
cannot bind the nucleotide) caused a 4-fold decrease in the
affinity of ADP for the D1 domain compared to the WT-
K524AD2 mutant (Figure 1A, Table S2). This 4-fold decrease in
ADP binding to the D1 domain of R155H when the D2
domain cannot bind the nucleotide is fully consistent with the
ITC results using the truncated ND1 protein.10,16 These
complementary experiments underscore the importance of
cross-talk for nucleotide binding in the D1 and D2 ATPase
rings.10,23 In contrast to the ADP binding results, we did not
observe a difference in ATP binding to the R155H−K524AD2
mutation compared to WT-K524AD2 (Figure 1B, and Table
S2). In addition, binding of ADP and ATP to the D2 domain
(K251AD1 mutations) was the same for WT p97 and the
R155H mutant (Figure S2 and Table S2).
Table 1. Binding Constants for ADP/p97 Complexes
SPR binding constants
ka × 10
5 (M−1 s−1)a kd (s
−1)a KD (nM)
b
WT D1 6.15 ± 0.03 0.063 ± 0.001 110 ± 22
WT D2 1.85 ± 0.02 0.98 ± 0.02 5500 ± 2200
R155H D1 7.70 ± 0.09 0.141 ± 0.001 203 ± 20
R155H D2 2.58 ± 0.07 2.32 ± 0.06 10 700 ± 2000
A232E D1 18.1 ± 0.10 0.131 ± 0.001 152 ± 104
A232E D2 3.02 ± 0.09 2.66 ± 0.08 9300 ± 2400
fluorescence anisotropy binding constants
KD (nM)
c
WT D1 131 ± 11
R155H D1 185 ± 10
A232E D1 205 ± 16
aErrors are standard errors of the mean of the fit (duplicate data at
each concentration). bAverage KD value calculated from kinetic fits
(three independent experiments, each in duplicate). Errors are
standard deviation of the mean. cErrors are standard errors of the
mean of the fit (triplicate data at each concentration).
Figure 1. Representative SPR sensorgrams (black lines, n = 2) fit to a 1:1 kinetic binding model (orange lines) and normalized SPR responses taken
at equilibrium fit to a one-site binding curve for (a) ADP binding and (b) ATP binding to a D2 Walker A mutation (K524A) in both WT p97 and an
R155H mutant.
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We next sought to evaluate whether the MSP1 mutations
altered the conformational propensities of p97. We measured
binding of the cofactors p37 and p47 in the presence of ADP
(when the N-domain is in a “down” conformation, parallel to
the D1 domain) and ATP (when the N-domain adopts an “up”
out-of-plane conformation).9,10,16 Because each monomer of
the trimeric p37 and p47 adaptors has the potential to interact
with the N-domain of p97, we hypothesized that the
nucleotide-induced conformational changes in the N-domain
would have an effect on adaptor binding.
We previously used SPR to measure rat p47 and human p37
binding to WT and MSP1 mutations in the absence of
nucleotides.22 We found that rat p47 bound WT p97 with two
different KD values (26 nM and 1.4 μM). Two sites could be
attributed to two different binding sites within p47; a recent
study suggests that the UBX domain and the SHP box (a 14-
residue sequence located between the SEP and UBX domains)
could bind to p97 at distinct sites on either the same or
adjacent p97 monomers.24 Other factors contributing to the
two KD values could include conformational changes/
heterogeneity in p97 or the binding of p47 monomers.22 By
contrast, binding of p37 was best fit with a 1:1 binding model.
However, at p37 concentrations above 256 nM, we observed
nonspecific binding, which limited us from measuring a possible
second binding site with micromolar affinity.
To determine if different nucleotide-bound conformations of
p97 affected adaptor binding, we used SPR to measure the
binding of p47 and p37 to WT and the MSP1 mutants in the
absence or presence of a saturating concentration of ADP or
ATP. We fit all data to a two-site model for consistency across
p47/p97 measurements. When no nucleotide was added,
human p47 bound to WT p97 with two KD values (22 nM
and 0.89 μM; Figure 2A), consistent with values for rat p47.22
The binding of p47 in the presence of ATP (KD’s = 49 nM and
1.93 μM) was similar to that of apo-p97. However, when p97
was bound to ADP, the high-affinity binding for p47 was 8-fold
weaker (184 nM) compared to that of apo-p97, and the off rate
was significantly faster (Figure 2A). This shift was also observed
for p47 binding to the ND1 domains (residues 1−458) of p97
(Figure S4), indicating that ADP binding to the D1 domain
played a large role in regulating the binding of p47 to WT p97.
The p37 adaptor also bound to apo-p97 and ATP-p97 with KD
values of 19 nM and 46 nM, respectively, but bound 8-fold
weaker to ADP-p97 (KD = 372 nM; Figure S5A).
In contrast to WT p97, MSP1 mutations lost their
nucleotide-induced conformational selection for p47 and p37.
We found that the binding affinities for p47 to the R155H
mutant were similar in the absence (KD’s = 19 nM and 0.35
μM) or presence of either ATP (KD’s = 14 nM and 0.68 μM)
or ADP (KD’s = 18 nM and 0.75 μM; Figure 2B). p37 also
exhibited similar binding affinities to the R155H mutant
regardless of the nucleotide-bound state (Figure S5B). To
ensure that the loss in nucleotide-dependent conformational
coupling was not specific for the R155H mutant, we also tested
p47 binding to the A232E MSP1 mutant. Similarly to R155H,
Figure 2. Binding of the adaptor p47 to p97. Normalized equilibrium binding response fit to a two-site equilibrium binding curve and representative
sensorgrams for FL human p47 (0−4 μM; n = 2 at each concentration) binding to (a) WT p97 or (b) R155H in the absence or presence of 100 μM
ADP or 100 μM ATP. The orange line represents the response range used to determine the equilibrium fit.
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we observed tight affinity binding of p47 to the ADP-bound
A232E mutant (KD’s = 21 nM and 0.71 μM; Figure S6).
On the basis of these studies, we propose a mechanistic
model (Figure 3) where the p37 and p47 adaptors prefer to
bind to the ATP-bound “up” conformation and may direct WT
p97 into this conformation upon binding. Although a recent
crystal structure of a p97 mutant in the apo-state shows the
enzyme adopting an N-domain “down” conformation,25 our
results suggest that in solution nucleotide-free p97 can readily
adopt the N-domain “up” conformation to promote tighter p47
binding. Additionally, nucleotide induced conformational
changes likely impact the binding of other adaptor proteins;
for instance, the ATP-bound form of WT p97 was also found to
enhance NPL4/UFD1 binding.26 In contrast to WT, MSP1
mutations maintain (or more readily adopt) a high-affinity
conformation that we propose is the “up” conformation seen in
the ATP-bound state of WT p97 (Figure 3).
More broadly, our results suggest that altered nucleotide-
induced conformational states in MSP1 mutants may be the
molecular basis for the biochemical properties observed in
these pathogenic mutations. The MSP1 mutants exhibit weaker
binding to ADP in the D1 domain when D2 is in a nucleotide
free state (Figure 1). This altered coupling may induce more
flexibility in p97’s conformation as it moves through the
ATPase cycle and could lead to the 3-fold higher ATPase
activity observed in MSP1 mutants.13−15 Moreover, ADP did
not inhibit binding of p47 and p37 to MSP1 mutant p97
(Figure 2 and Figure S5), suggesting that MSP1 mutations may
adopt the N-domain “up” conformation more easily than WT-
p97 when the ADP is bound to the D1 domain. This result is
consistent with the observation that MSP1 mutants bind more
p47 in cells compared to WT p9715,17,18MSP1 mutants bind
p47 with tight affinity, independent of the nucleotide-binding
state of p97. Results presented here pave the way for further
studies aimed at understanding how p97 ATPase activity and
conformational dynamics influence the function and stability of
p97-dependent protein complexes.
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